Hematolic drugs

The market for Hematolic drugs is worth about R132 million, which is a significant opportunity for your organisation. However, it's worth noting that this market is not growing, with zero year-on-year growth, so you'll need to be strategic to gain traction. The market is also quite concentrated, with only one supplier currently serving one department, so it may be challenging to break in. The good news is that there is a favourable allocation for smaller companies, with about 14% of the spend set aside for black-owned businesses, 10% for women-owned businesses, and 5% for youth-owned businesses. If I were you, I'd focus on building relationships with the relevant department and highlighting your organisation's unique strengths and ownership structure to try and secure a foothold in this market.

ProTenders Intelligence, powered by National Treasury BAS data